Date: 4-7 October, 2022
Venue: Maternushaus, Cologne, Germany
Attendees: Priyanka Kohli (Research Scientist, Metabolic Diseases), Akanksha Dixit (Research Scientist, Metabolic Diseases), Kirsty Holden (Senior BD Executive – Attending Virtually)
Evotec will be sponsoring this year’s European Cilia conference as well as showcasing its research on site in Cologne. Come visit us in person at booth #4.
If you wish to meet with us in Cologne, get in touch via the form below, we will be happy to arrange a meeting.
Learn more about the Cilia Conference.
Date: 06 October 2022
Location: Alexandria Point (Green Acres Campus Point, 10300 Campus Point Dr, San Diego, CA 92121)
Attendee: David Cerny
We hope to see you at Southern California Chapter Fall 2022 Meeting!
Learn more about Southern California Chapter Fall 2022 Meeting
Date: 7 October 2022
Venue: Heidelberg, Germany
Attendees: Friedrich Reinhard (VP Academic Partnerships) and Laurie Sarrat (Business Development Manager)
Evotec will be attending at this year’s BioRN Annual conference as well as showcasing its research on site in Heidelberg.
If you wish to meet with us in Heidelberg, get in touch via the form below, we will be happy to arrange a meeting.
Learn more about the BioRN Annual Conference
Date: 16 - 17 November 2022
Location: Madrid, Spain
Attendees: Domenico Augelli (Clinical Manager, Clinical Development)
Tags: Events
Date: 4 - 7 October, 2022
Venue: Crowne Plaza Dublin - Blanchardstown
Attendees: Francesca Bernardini (VP In Vitro Biology) and Stephanie Sandiford (Senior Scientist II, Anti-Infectives)
Stephanie Sandiford will be presenting a poster: Abstract Number EA56, Wednesday, 5 October 2022 17.00-18.30, Thursday, 6 October 2022 17.15-18.15
Rapid endpoint method for the quantification of Mycobacterium tuberculosis (Mtb) subjected to three different treatment regimens within the hollow fibre system (HFS)
If you wish to meet with us in Münster, get in touch via the form below, we will be happy to arrange a meeting.
Learn more about the 10th GSCN Conference & 20 years of Stem Cell Network NRW.
Date: 12-14 October, 2022
Venue: PACIFICO Yokohama, Japan
Attendees: Nick Johnson, Megumi Ruben and Adam Stoten
Evotec will be at BioJapan, Asia's largest partnering event, in Yokohama. Join our experts to learn more about Evotec's capabilities and solutions for drug discovery and development.
If you wish to meet with us at BioJapan, get in touch via the Partnering system or the form below, we will be happy to arrange a meeting.
Date: 13 September, 2022
Venue: LifeHub Lyon, France
Attendees: Lilia Boucinha, Team Leader, Global Bioinformatics
Lilia will be a panelist on the session entitled "Sustainability and digitalization of R&D in the era of open data and open innovation"
If you wish to meet with us in Lyon, get in touch via the form below, we will be happy to arrange a meeting.
Learn more about the Constellab Connect 2022
The importance of viral filtration studies
Biological therapeutics need to meet strict safety criteria. Virus safety is ensured through complementary manufacturing and quality control measures. Virus filtration is a critical element in this process, and viral filtration studies have become a key step in bioprocessing over the past decades. They are required by most regulators to bring a biologic to the market. The purpose is to assure that the final medicinal product is safe from the potential risk of viral contamination.
The quality of the design of such studies is key: when inappropriately designed, they may lead to undesired results such as non-representative filter fouling or virus breakthrough.
The characteristics of end-to-end continuous filtration
Continuous processing is a modern manufacturing method for biologicals, e.g. monoclonal antibodies (mAb). Consequently, also continuous viral clearance has to be investigated. Compared to batch filtration, continuous end-to-end processes present new challenges to the operation and validation of the viral filter:
Consequences for assessing viral clearance in continuous end-to-end filtration
This, in turn, means that assessment of viral clearance in continuous viral filtration may require studies spanning over several days and also novel virus-spiking strategies. This type of assessment is needed to adequately demonstrate a high level of viral clearance while ensuring the filters are not overloaded with virus and are consistent with real-life manufacturing conditions.
A team of scientists at Just- Evotec Biologics has performed studies to identify a robust virus filter that retains virus despite high load challenges and low operation pressures. Key findings were:
Summary and outlook
While bioprocessing technologies have evolved rapidly during the past decades, multiple factors such as increased cost, quality and production pressures are calling for further advances. At the same time, regulatory requirements are evolving and sophisticated safety testing has become a key prerequisite for market approval of novel biologics.
The team at JUST - Evotec Biologics has therefore kicked off an initiative to spearhead the development of next-generation bioprocessing technologies such as continuous end-to-end viral filtration.
Future work of the group will include optimization of the surrogate virus spiking and testing techniques as well as testing other virus filters for robustness of virus clearance at low flux/pressure conditions.
Interested in further information about Just-Evotec Biologics? Please visit our site.
For more information download the full poster.
Date: 2-5 October, 2022
Location: Phoenix, Arizona, USA
Attendees: Yalda Sedaghat (Project Lead, ASO Platform)
Evotec will be attending and showcasing its research on site in Phoenix at the 18th Annula Meeting of the Oligonucleotide Therapeuitcs Society .
The oligonucleotide therapeutics platform at Evotec: fully integrated RNA drug discovery
Yalda Sedaghat, Project Lead, ASO Platform at Evotec, will be presenting.
If you wish to meet with us in Phoenix, get in touch via the form below, we will be happy to arrange a meeting.
Learn more about the Annual Meeting of the Oligonucleotide Therapeutics Society